汉维宠仕®
Hanvet Pet Health
兽用

美洛昔康内服混悬液说明书

美昔
Melocam

【兽药名称】 通用名：美洛昔康内服混悬液
商品名：美昔®
英文名：Meloxicam Oral Suspension
汉语拼音：Meiluoxikang Neifu Hunxuanye

【主要成分】 美洛昔康

【性　　状】 本品为淡黄绿色混悬液。

【药理作用】 **药效学** 本品为解热镇痛非甾体抗炎药（NSAIDs），主要通过抑制环氧化酶（COX）的活性，减少前列腺素（PGs）的产生而发挥其镇痛的作用。本品能选择性地抑制环氧化酶（COX-2），而对环氧化酶（COX-1）的抑制作用较轻。因此，与其它同类药相比，本品对胃肠道或肾脏的不良反应较轻。
药动学 美洛昔康经内服吸收很好，血药浓度达峰时间快，在犬体内生物利用度高，单剂量口服该药后消除半衰期约为24h，吸收后能分布到动物的所有组织中，包括中枢静脉系统、肌肉层和发生炎症的关节。

【药物相互作用】 1. 同时使用一种以上的NSAID可能通过协同作用而增加胃肠道溃疡及出血的可能性。
2. 内服抗凝剂、氨苄噻哌啶、肝素、溶栓药，可增加出血的可能。
3. 美洛昔康能增加氨甲蝶呤的血液毒性、环孢素的肾毒性。
4. 可能使利尿脱水犬发生急性肾功能不全，故使用美洛昔康和利尿剂的犬应保证充足的血容量。

【适　应　证】 用于控制犬急慢性骨关节炎引起的疼痛和炎症，以及术后止痛等。

【用法与用量】 以本品计。内服：用前充分摇匀，每1kg体重，犬首次量0.133ml，维持量0.067ml，一日1次，连用7日。因存在个体差异，请遵医嘱。

【不良反应】 主要是食欲不振、呕吐、腹泻。通常是暂时性的，极少数引起死亡。

【注意事项】 1.不推荐用于妊娠期、泌乳期或不足6周龄的犬。
2.禁用于对本品过敏的犬。
3.存在肾毒性的潜在风险，请慎用于脱水、血容量减少或低血压的动物。
4.禁用于胃肠道溃疡或出血，肝脏、心脏或肾脏功能受损及出血异常的犬。
5.禁与糖皮质激素、其他非类固醇类消炎药或抗凝血剂合用。
6.对NSAIDs过敏的人应避免接触本品。远离儿童。

【规　　格】 按$C_{14}H_{13}N_3O_4S_2$计算　1）10ml:15mg　2）32ml:48mg

【包　　装】 1瓶/盒。　10ml:15mg

【贮　　藏】 遮光，密闭保存。

【新兽药注册证书号】（2014）新兽药证字31号。

【有　效　期】 2年。

【批准文号】 兽药字(2015)150252469

【生产企业】 齐鲁动物保健品有限公司
山东省济南市工业北路243号

【电话/传真】 400-875-2220

【网　　址】 www.hanvet.com

汉维宠仕®
Hanvet Pet Health
兽用

Meloxicam Oral Suspension

美昔
Melocam

NAME OF THE VETERINARY MEDICINAL PRODUCT Meloxicam Oral Suspension

ACTIVE INGREDIENT Meloxicam

PHARMACEUTICAL FORM
The suspension formulation is a yellowish viscous suspension with the odor of honey.

PHARMACOLOGICAL EFFECTS
Pharmacology Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).
Pharmacokinetics Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 7.5 hours. Bioavailability in dogs is high. When the product is administrated according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment. Meloxicam is eliminated with a half-life of 24 hours. After absorption it can be distributed to all the tissues including central venous system, muscle layer and the joints which have an inflammation.
Interaction with other medicinal products and other forms of interaction
① Concomitant use with other anti-inflammatorydrugs, such as NSAIDs or corticosteroids may possess the potential to induce gastrointestinal ulcerations and/or perforations.
② Concurrent administration with anticoagulant, heparin and hemolysis medicine could increase the risk of bleeding.
③ Meloxicam could increase the hematotoxicity of methotrexate, and the nephrotoxicity of ciclosporin.
④ Ensure the blood volumn of dogs using meloxicam and diuretic, because meloxicam may cause acute renal insufficiency of dehydration dogs.
⑤ Combined with cholestyramine in the gastrointestinal tract, meloxicam could exclude faster.

INDICATIONS FOR USE
Meloxicam oral suspension is indicated in the control of pain and inflammation associated with osteoarthritis of dogs. It is also used in the control of pain and inflammation following surgery.

DOSAGE AND ADMINISTRATION
Oral use. Use the lowest effective dose for the shortest duration consistent with individual response. Initial treatment is a single dose of 0.133mL/kg body weight on the first day. Treatment is to be continued once daily by oral administration(at 24-hour intervals) at a maintenance dose of 0.067mL/kg body weight. The treatment should last at least 7 days.
Shake well before use then remove cap. The product may be either mixed with food or placed directly into the mouth. The suspension can be given using the measuring syringe provided in the package.

ADVERSE REACTIONS
Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported. These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment.

CONTRAINDICATIONS
1. Not recommended for use in pregnant, lactating or less than 6 weeks dogs.
2. Should not be used in dogs with known hypersensitivity to the active substance.
3. Should be used with caution in dehydration, low blood volumn and hypotensive animals, due to the potential risk of renal toxicity.
4. Should not be used in dogs suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
5. Do not combine with glucocorticoids, other non-steroidal anti-inflammatory drugs or anticoagulants.
6. People with known hypersensitivity to NSAIDs should avoid contacting with the product. Keep it out the reach of childen.

WITHDRAWAL PERIOD(S) Not applicable.

HOW SUPPLIED 32ml:48mg
Nature and composition of immediate packaging

STORAGE INFORMATION Keep away from sunlight, sealed in dry place

SHELF-LIFE 2 years